You are here
Home > About RedHill Biopharma Ltd

RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma

The first patients have been screened and a first patient has been dosed in the open-label, dose escalation Phase Ib/II study with YELIVA® (ABC294640) for multiple myeloma The Phase Ib/II clinical study is intended to evaluate the safety and efficacy of YELIVA® in up to 77 patients with refractory or relapsed multiple myeloma who have […]